A Phase II Trial of Ifosfamide, Carboplatin, and Etoposide (ICE) Chemotherapy in Combination With Rituximab as Salvage Therapy
- Determine the chemosensitivity rate in patients with recurrent or refractory
non-Hodgkin's lymphoma treated with ifosfamide, carboplatin, and etoposide (ICE) in
combination with rituximab.
- Determine whether the addition of rituximab changes the toxicity profile of the ICE
chemotherapy regimen in these patients.
OUTLINE: Patients receive rituximab IV on days 1, 8, and 15 and ifosfamide IV over 1 hour,
etoposide IV over 2 hours, and carboplatin IV on days 2-4. Treatment continues every 21 days
for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who
are not candidates for autologous stem cell transplantation may receive 1-4 more courses of
chemotherapy without rituximab.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 19-39 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Julie M. Vose, MD
University of Nebraska
United States: Federal Government
|UNMC Eppley Cancer Center at the University of Nebraska Medical Center||Omaha, Nebraska 68198-7680|